Lianyungang, China

Xinlu Li

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 9.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2025

where 'Filed Patents' based on already Granted Patents

4 patents (USPTO):

Title: Innovator Xinlu Li: Advancements in Protein Kinase Inhibitors

Introduction

Xinlu Li is a notable inventor hailing from Lianyungang, China. With a portfolio of two patents, he has made significant contributions to the field of pharmaceutical sciences, particularly in the development of protein kinase inhibitors. His work focuses on enhancing the efficacy and safety of drug compounds aimed at treating diseases related to protein kinases.

Latest Patents

Xinlu Li's latest patents represent groundbreaking advancements in pharmaceutical formulations. One of his notable inventions is the "Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal," which discloses a citrate salt crystal of a specific compound. This formulation improves upon previous iterations in bioavailability, hygroscopicity, stability, solubility, and purity. The compound is particularly valuable for treating protein kinase-related diseases.

Another patent by Xinlu details "Pyridine-substituted 2-aminopyridine protein kinase inhibitors." This invention encompasses pharmaceutically acceptable acid salts of these derivatives, offering novel preparation methods and pharmaceutical compositions. His work highlights the potential of these inhibitors for treating a range of diseases associated with protein kinase dysfunction.

Career Highlights

Throughout his career, Xinlu Li has collaborated with prominent organizations, including Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Centaurus Biopharma Co., Ltd. His innovative approach to drug development has positioned him as a key figure in the pharmaceutical industry, contributing to advancements that may lead to effective treatments for complex diseases.

Collaborations

Xinlu has worked alongside talented colleagues, including Feng Gong and Rui Zhao. These collaborations have enabled the cross-pollination of ideas and expertise, further enhancing the quality and impact of the research undertaken. Their joint efforts contribute to the ongoing evolution and potential commercialization of new therapeutic interventions.

Conclusion

With two patents to his name and a clear focus on the development of protein kinase inhibitors, Xinlu Li continues to push the boundaries of pharmaceutical innovation. His contributions are vital to improving treatment options for diseases linked to protein kinases, establishing him as an influential inventor in the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…